Phase 1 N=40 Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children
Influenza
Primary: Number of Subjects Reporting Fever Grade 2 or Higher — 11; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=22 A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)
Type 2 Diabetes Mellitus
Primary: Recovery Time (Rt[65] From Insulin-induced Hypoglycemia — 103; 71 minutes — p=0.005
Phase 1 N=30 A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions
Healthy
Primary: Area Under the Curve From Time Zero to 72 Hours [AUC (0-72)] — 419.9; 442.1 nanogram hour per milliliter (ng*h/mL)
Phase 1 N=76 A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
Healthy
Primary: Change From Baseline in Body Weight — 2.32; 4.23; 2.87 kilograms
Phase 1 N=25 A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
Alzheimer's Disease
Primary: Mean Cortical to Cerebellum SUVR — 1.416; 1.005; 1.407; 1.007 SUVR
Phase 1 N=20 A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
Alzheimer Disease
Primary: Florbetapir-PET Scan Quality — 0; 0; 0; 0 florbetapir scans
Phase 1 N=9 A Study of 18F-AV-45 in Healthy Volunteers
Alzheimer Disease
Primary: Whole Body Radiation Dosimetry — 0.0186; 0.0136; 0.01; 0.00624 mSv/MBq
Phase 1 N=96 Switching Study From Warfarin to Rivaroxaban
Venous Thrombosis
Primary: Emax (Maximum Effect) on Prothrombin Time (PT) (Coagulation Test) — 4.393; 1.884; 1.573 ratio — p=<0.0001
Phase 1 N=40 Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers
Healthy
Primary: Linagliptin: Maximum Measured Concentration (Cmax) — 5.36; 5.39 nmol/L
Phase 1 N=30 A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age
Head Lice
Primary: Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points — 0.00000; 0.02528; 0.08192; 0.20075 ng/mL
Phase 1 N=15 A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Lymphoma, Follicular
Primary: Area Under the Curve (AUC) at 0 to 120, 0 to 168, and 0 to Infinity Hours — 1.04; 1.18; 1.39 %ID.h/mL
Phase 1 N=60 Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)
Hepatitis C
Primary: Area Under the Concentration Curve (AUC) From Hour 0 to the Final Quantifiable Sample (AUCtf) for Boceprevir Tablets Versus Capsules in Fed State — 7385; 6644 ng*hr/mL
Phase 1 N=131 A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 6-Month Endpoint — -0.08; 0.06; -0.15; 0.04 percent glycosylated hemoglobin (HbA1c) — p=0.623
Phase 1 N=26 QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing. — 2; 11 msec
Phase 1 N=24 Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Sexual Dysfunctions, Psychological
Primary: Flibanserin: Area Under the Curve; AUC_0-∞ — 2570 ng*h/mL